Ran GTPase promotes cancer progression via Met recepto-rmediated downstream signaling

Lists

Yuen, Hiu-Fung, Chan, Ka-Kui, Platt-Higgins, Angela, Dakir, EL-Habib, Matchett, Kyle, Haggag, Yusuf Ahmed, Jithesh, Puthen, Habib, Tanwir, Faheem, Ahmed, Fennell, Dean, Morgan, Richard ORCID: https://orcid.org/0000-0002-8721-4479, Rudland, Philip and El-Tanani, Mohamed (2016) Ran GTPase promotes cancer progression via Met recepto-rmediated downstream signaling. Oncotarget, 7 (46). pp. 75854-75864.

Preview

PDF
Ran Oncotarget 2016.pdf - Published Version
Available under License Creative Commons Attribution.
Download (1MB) | Preview

Official URL: https://doi.org/10.18632/oncotarget.12420

Abstract

It has been shown previously that cancer cells with an activated oncogenic pathway, including Met activation, require Ran for growth and survival. Here, we show that knockdown of Ran leads to a reduction of Met receptor expression in several breast and lung cancer cell lines. This, in turn suppressed HGF expression and the Met-mediated activation of the Akt pathway, as well as cell adhesion, migration, and invasion. In a cell line model where Met amplification has previously been shown to contribute to gefitinib resistance, Ran knockdown sensitized cells to gefitinib-mediated inhibition of Akt and ERK1/2 phosphorylation and consequently reduced cell proliferation. We further demonstrate that Met reductionmediated by knockdown of Ran, occurs at the post-transcriptional level, probably via a matrix metalloproteinase. Moreover, the level of immunoreactive Ran and Met are positively associated in human breast cancer specimens, suggesting that a high level of Ran may be a prerequisite for Met overexpression. Interestingly, a high level of immunoreactive Ran dictates the prognostic significance of Met, indicating that the co-overexpression of Met and Ran may be associated with cancer progression and could be used in combination as a prognostic indicator.

Item Type:	Article
Identifier:	10.18632/oncotarget.12420
Keywords:	Ran GTP, C-Met, breast cancer, lung cancer, gefitinib
Subjects:	Natural sciences > Cell and molecular biology
Related URLs:	Organisation Publisher
Depositing User:	Richard Morgan
Date Deposited:	09 Jul 2020 08:53
Last Modified:	06 Feb 2024 16:03
URI:	https://repository.uwl.ac.uk/id/eprint/7103

Downloads

Downloads per month over past year

Actions (login required)

View Item

References

1. Clarke PR and Zhang C. Spatial and temporal coordination of mitosis by Ran GTPase. Nat Rev Mol Cell Biol. 2008; 9:464-477.

2. Rensen WM, Mangiacasale R, Ciciarello M and Lavia P. The GTPase Ran: regulation of cell life and potential roles in cell transformation. Front Biosci. 2008; 13:4097-4121.

3. Xia F, Lee CW and Altieri DC. Tumor cell dependence on Ran-GTP-directed mitosis. Cancer Res. 2008; 68:1826-1833.

4. Ly TK, Wang J, Pereira R, Rojas KS, Peng X, Feng Q, Cerione RA and Wilson KF. Activation of the Ran GTPase is subject to growth factor regulation and can give rise to cellular transformation. J Biol Chem. 2010; 285:5815-5826.

5. Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O’Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS and El-Tanani M. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. Clin Cancer Res. 2012; 18:380-391.

6. Yoon SO, Shin S, Liu Y, Ballif BA, Woo MS, Gygi SP and Blenis J. Ran-binding protein 3 phosphorylation links the Ras and PI3-kinase pathways to nucleocytoplasmic transport. Mol Cell. 2008; 29:362-375.

7. Kurisetty VV, Johnston PG, Johnston N, Erwin P, Crowe P, Fernig DG, Campbell FC, Anderson IP, Rudland PS and El-Tanani MK. RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin. Oncogene. 2008; 27:7139-7149.

8. Dallol A, Hesson LB, Matallanas D, Cooper WN, O’Neill E, Maher ER, Kolch W and Latif F. RAN GTPase is a RASSF1A effector involved in controlling microtubule organization. Curr Biol. 2009; 19:1227-1232.

9. Amato R, Scumaci D, D’Antona L, Iuliano R, Menniti M, Di Sanzo M, Faniello MC, Colao E, Malatesta P, Zingone A, Agosti V, Costanzo FS, Mileo AM, et al. Sgk1 enhances RANBP1 transcript levels and decreases taxol sensitivity in RKO colon carcinoma cells. Oncogene. 2013; 32:4572-4578.

10. Talarico C, D’Antona L, Scumaci D, Barone A, Gigliotti F, Fiumara CV, Dattilo V, Gallo E, Visca P, Ortuso F, Abbruzzese C, Botta L, Schenone S, et al. Preclinical model in HCC: the SGK1 kinase inhibitor SI113 blocks tumor progression in vitro and in vivo and synergizes with radiotherapy. Oncotarget. 2015; 6:37511-37525. doi:10.18632/oncotarget.5527.

11. Yuen HF, Gunasekharan VK, Chan KK, Zhang SD, Platt-Higgins A, Gately K, O’Byrne K, Fennell DA, Johnston PG, Rudland PS and El-Tanani M. RanGTPase: a candidate for Myc-mediated cancer progression. J Natl Cancer Inst. 2013; 105:475-488.

12. Jiang WG, Grimshaw D, Lane J, Martin TA, Abounader R, Laterra J and Mansel RE. A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clin Cancer Res. 2001; 7:2555-2562.

13. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG and Salgia R. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005; 65:1479-1488.

14. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, Del Grammastro M, Sciarrotta MG, Buttitta F, Incarbone M, Toschi L, Finocchiaro G, Destro A, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 2009; 27:1667-1674.

15. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, Gibbs JB and Pan BS. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 2007; 67:2081-2088.

16. Mueller KL, Hunter LA, Ethier SP and Boerner JL. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res. 2008; 68:3314-3322.

17. Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, Snider J, Davies SR, Swiatek PJ, Cottingham S, Watson MA, Ellis MJ, Sigler RE, Furge KA and Vande Woude GF. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A. 2009; 106:12909-12914.

18. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316:1039-1043.

19. Cappuzzo F, Janne PA, Skokan M, Finocchiaro G, Rossi E, Ligorio C, Zucali PA, Terracciano L, Toschi L, Roncalli M, Destro A, Incarbone M, Alloisio M, Santoro A and Varella-Garcia M. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol. 2009; 20:298-304.

20. Ponzo MG, Lesurf R, Petkiewicz S, O’Malley FP, Pinnaduwage D, Andrulis IL, Bull SB, Chughtai N, Zuo D, Souleimanova M, Germain D, Omeroglu A, Cardiff RD, Hallett M and Park M. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A. 2009; 106:12903-12908.

21. Xu K, Usary J, Kousis PC, Prat A, Wang DY, Adams JR, Wang W, Loch AJ, Deng T, Zhao W, Cardiff RD, Yoon K, Gaiano N, et al. Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer. Cancer Cell. 2012; 21:626-641.

22. Sadiq AA and Salgia R. MET As a Possible Target for Non-Small-Cell Lung Cancer. J Clin Oncol. 2013.

23. Sadiq AA and Salgia R. MET as a possible target for non-small-cell lung cancer. J Clin Oncol. 2013; 31:1089-1096.

24. Yang YM, Lee CG, Koo JH, Kim TH, Lee JM, An J, Kim KM and Kim SG. Galpha12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4alpha inactivation, which causes c-Met induction. Oncotarget. 2015; 6:19055-19069. doi:10.18632/oncotarget.3957.

25. Wang D, Li Z, Messing EM and Wu G. Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM. J Biol Chem. 2002; 277:36216-36222.

26. Boccaccio C and Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer. 2006; 6:637-645.

27. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S and Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003; 3:347-361.

28. Tulasne D, Deheuninck J, Lourenco FC, Lamballe F, Ji Z, Leroy C, Puchois E, Moumen A, Maina F, Mehlen P and Fafeur V. Proapoptotic function of the MET tyrosine kinase receptor through caspase cleavage. Mol Cell Biol. 2004; 24:10328-10339.

29. Foveau B, Leroy C, Ancot F, Deheuninck J, Ji Z, Fafeur V and Tulasne D. Amplification of apoptosis through sequential caspase cleavage of the MET tyrosine kinase receptor. Cell Death Differ. 2007; 14:752-764.

30. Jeffers M, Taylor GA, Weidner KM, Omura S and Vande Woude GF. Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway. Mol Cell Biol. 1997; 17:799-808.

31. Carter S, Urbe S and Clague MJ. The met receptor degradation pathway: requirement for Lys48-linked polyubiquitin independent of proteasome activity. J Biol Chem. 2004; 279:52835-52839.

32. Nath D, Williamson NJ, Jarvis R and Murphy G. Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J Cell Sci. 2001; 114:1213-1220.

33. Schelter F, Kobuch J, Moss ML, Becherer JD, Comoglio PM, Boccaccio C and Kruger A. A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. J Biol Chem. 2010; 285:26335-26340.

34. Morgan-Lappe SE, Tucker LA, Huang X, Zhang Q, Sarthy AV, Zakula D, Vernetti L, Schurdak M, Wang J and Fesik SW. Identification of Ras-related nuclear protein, targeting protein for Xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Res. 2007; 67:4390-4398.

35. Peters S and Adjei AA. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol. 2012; 9:314-326.

36. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007; 104:20932-20937.

37. Scagliotti GV, Novello S, Schiller JH, Hirsh V, Sequist LV, Soria JC, von Pawel J, Schwartz B, Von Roemeling R and Sandler AB. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer. 2012; 13:391-395.

38. Surati M, Patel P, Peterson A and Salgia R. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther. 2011; 11:1655-1662.

39. Kuersten S, Ohno M and Mattaj IW. Nucleocytoplasmic transport: Ran, beta and beyond. Trends Cell Biol. 2001; 11:497-503.

40. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L and Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 2011; 278:28-45.

41. Yuen HF, Chan YK, Grills C, McCrudden CM, Gunasekharan V, Shi Z, Wong AS, Lappin TR, Chan KW, Fennell DA, Khoo US, Johnston PG and El-Tanani M. Polyomavirus enhancer activator 3 protein promotes breast cancer metastatic progression through Snail-induced epithelial-mesenchymal transition. J Pathol. 2011; 224:78-89.

Tools

CORE (COnnecting REpositories)

The University of West London

Ran GTPase promotes cancer progression via Met recepto-rmediated downstream signaling

Abstract

Downloads

Actions (login required)

Menu